Gilead buys out cash-hungry partner Jounce’s antibody for $67M

Gilead Sciences has bought out Jounce Therapeutics’ anti-CCR8 antibody for $67 million, taking over full R&D and commercial rights to the experimental cancer immunotherapy drug. The deal will give Jounce enough cash to keep operating into the third quarter of 2024, said Cowen analyst Boris Peaker. But it means the…

...

Click to view original post